Literature DB >> 19098997

Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma.

Valeria R Mas1, Daniel G Maluf, Kellie J Archer, Kenneth Yanek, Xiangrong Kong, Laura Kulik, Chris E Freise, Kim M Olthoff, Rafik M Ghobrial, Paula McIver, Robert Fisher.   

Abstract

The role of chronic hepatitis C virus (HCV) in the pathogenesis of HCV-associated hepatocellular carcinoma (HCC) remains controversial. To understand the transition from benign to malignant, we studied the gene expression patterns in liver tissues at different stages, including normal, cirrhosis, and different HCC stages. We studied 108 liver tissue samples obtained from 88 distinct patients (41 HCV-cirrhotic tissues, 17 HCV-cirrhotic tissues from patients with HCC, and 47 HCV-HCC tissues). Differentially expressed genes (DEG) were studied by use of high-density oligonucleotide arrays. Among probe sets identified as differentially expressed via the F test, all pairwise comparisons were performed. Cirrhotic tissues with and without concomitant HCC were further evaluated, and a classifier was used to predict whether the tissue type was associated with HCC. Differential expression profiles were analyzed using Interaction Networks and Functional Analysis. Characteristic gene signatures were identified when normal tissue was compared with cirrhosis, cirrhosis with early HCC, and normal with HCC. Pathway analysis classified the cellular and biological functions of the DEG as related to cellular growth and proliferation, cell death and inflammatory disease in cirrhosis; cell death, cell cycle, DNA replication, and immune response in early HCCs; and cell death, cell growth and proliferation, cell cycle, and DNA repair in advanced HCCs. Characteristic gene signatures were identified at different stages of HCV-HCC progression. A set of genes were identified to predict whether the cirrhotic tissue was associated with HCC.

Entities:  

Mesh:

Year:  2008        PMID: 19098997      PMCID: PMC2605622          DOI: 10.2119/molmed.2008.00110

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  39 in total

Review 1.  Current understanding of the biology of advanced bladder cancer.

Authors:  Sana Al-Sukhun; Maha Hussain
Journal:  Cancer       Date:  2003-04-15       Impact factor: 6.860

2.  Summaries of Affymetrix GeneChip probe level data.

Authors:  Rafael A Irizarry; Benjamin M Bolstad; Francois Collin; Leslie M Cope; Bridget Hobbs; Terence P Speed
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

3.  Liver organ allocation for hepatocellular carcinoma: are we sure?

Authors:  J Wallis Marsh; Igor Dvorchik
Journal:  Liver Transpl       Date:  2003-07       Impact factor: 5.799

4.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

5.  affy--analysis of Affymetrix GeneChip data at the probe level.

Authors:  Laurent Gautier; Leslie Cope; Benjamin M Bolstad; Rafael A Irizarry
Journal:  Bioinformatics       Date:  2004-02-12       Impact factor: 6.937

Review 6.  Chromosomal instability and human hepatocarcinogenesis.

Authors:  N Nishida; T Nishimura; T Ito; T Komeda; Y Fukuda; K Nakao
Journal:  Histol Histopathol       Date:  2003-07       Impact factor: 2.303

7.  Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Norio Iizuka; Masaaki Oka; Hisafumi Yamada-Okabe; Minekatsu Nishida; Yoshitaka Maeda; Naohide Mori; Takashi Takao; Takao Tamesa; Akira Tangoku; Hisahiro Tabuchi; Kenji Hamada; Hironobu Nakayama; Hideo Ishitsuka; Takanobu Miyamoto; Akira Hirabayashi; Shunji Uchimura; Yoshihiko Hamamoto
Journal:  Lancet       Date:  2003-03-15       Impact factor: 79.321

Review 8.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

9.  Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival.

Authors:  J Wallis Marsh; Sydney D Finkelstein; Anthony J Demetris; Patricia A Swalsky; Eizaburo Sasatomi; Andriy Bandos; Michael Subotin; Igor Dvorchik
Journal:  Liver Transpl       Date:  2003-07       Impact factor: 5.799

Review 10.  Molecular pathogenesis of urothelial bladder cancer.

Authors:  D Theodorescu
Journal:  Histol Histopathol       Date:  2003-01       Impact factor: 2.303

View more
  139 in total

1.  MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy.

Authors:  Xinling Zhang; Leina Ma; Jieqiong Qi; Hui Shan; Wengong Yu; Yuchao Gu
Journal:  Mol Cell Biochem       Date:  2015-08-29       Impact factor: 3.396

2.  Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer.

Authors:  Sun-Hye Jeong; Han-Byul Kim; Min-Chul Kim; Ji-Min Lee; Jae Ho Lee; Jeong-Hwan Kim; Jin-Woo Kim; Woong-Yang Park; Seon-Young Kim; Jae Bum Kim; Haeryoung Kim; Jin-Man Kim; Hueng-Sik Choi; Dae-Sik Lim
Journal:  J Clin Invest       Date:  2018-02-05       Impact factor: 14.808

3.  FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53.

Authors:  Updesh Dixit; Ashutosh K Pandey; Zhihe Liu; Sushil Kumar; Matthew B Neiditch; Kenneth M Klein; Virendra N Pandey
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

4.  MicroRNA-206 antagomiR‒enriched extracellular vesicles attenuate lung ischemia‒reperfusion injury through CXCL1 regulation in alveolar epithelial cells.

Authors:  Jun Cai; Ricardo Gehrau; Zhenxiao Tu; Victoria Leroy; Gang Su; Junyi Shang; Valeria R Mas; Amir Emtiazjoo; Andres Pelaez; Carl Atkinson; Tiago Machuca; Gilbert R Upchurch; Ashish K Sharma
Journal:  J Heart Lung Transplant       Date:  2020-09-28       Impact factor: 10.247

5.  Hepatitis C virus RNA functionally sequesters miR-122.

Authors:  Joseph M Luna; Troels K H Scheel; Tal Danino; Katharina S Shaw; Aldo Mele; John J Fak; Eiko Nishiuchi; Constantin N Takacs; Maria Teresa Catanese; Ype P de Jong; Ira M Jacobson; Charles M Rice; Robert B Darnell
Journal:  Cell       Date:  2015-03-12       Impact factor: 41.582

6.  Donor Hepatic Steatosis Induce Exacerbated Ischemia-Reperfusion Injury Through Activation of Innate Immune Response Molecular Pathways.

Authors:  Ricardo C Gehrau; Valeria R Mas; Catherine I Dumur; Jihee L Suh; Ashish K Sharma; Helen P Cathro; Daniel G Maluf
Journal:  Transplantation       Date:  2015-12       Impact factor: 4.939

7.  Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients.

Authors:  Jens U Marquardt; Kerstin Fischer; Katharina Baus; Anubha Kashyap; Shengyun Ma; Markus Krupp; Matthias Linke; Andreas Teufel; Ulrich Zechner; Dennis Strand; Snorri S Thorgeirsson; Peter R Galle; Susanne Strand
Journal:  Hepatology       Date:  2013-07-30       Impact factor: 17.425

8.  Hepatocellular carcinoma in Hepatitis C genotype 4 after viral clearance and in absence of cirrhosis: two case reports.

Authors:  Moutaz Derbala; Aliaa Amer
Journal:  Cases J       Date:  2009-09-15

9.  Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old.

Authors:  Dilek Colak; Muhammad A Chishti; Al-Bandary Al-Bakheet; Ahmed Al-Qahtani; Mohamed M Shoukri; Malcolm H Goyns; Pinar T Ozand; John Quackenbush; Ben H Park; Namik Kaya
Journal:  Mol Cancer       Date:  2010-06-12       Impact factor: 27.401

10.  Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma.

Authors:  Valeria De Giorgi; Alessandro Monaco; Andrea Worchech; Marialina Tornesello; Francesco Izzo; Luigi Buonaguro; Francesco M Marincola; Ena Wang; Franco M Buonaguro
Journal:  J Transl Med       Date:  2009-10-12       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.